172 related articles for article (PubMed ID: 15104947)
1. [Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases].
García Hernández FJ; Ocaña Medina C; Mateos Romero L; Molinillo López J; Arias Zambrano A; González León R; Sánchez Román J
Med Clin (Barc); 2004 Apr; 122(13):501-4. PubMed ID: 15104947
[TBL] [Abstract][Full Text] [Related]
2. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
3. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
[TBL] [Abstract][Full Text] [Related]
5. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis.
Zachariae H; Halkier-Sørensen L; Bjerring P; Heickendorff L
Acta Derm Venereol; 1996 May; 76(3):236-8. PubMed ID: 8800308
[TBL] [Abstract][Full Text] [Related]
6. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
Cochrane Database Syst Rev; 2000; 1998(2):CD000953. PubMed ID: 10796395
[TBL] [Abstract][Full Text] [Related]
7. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
8. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
[TBL] [Abstract][Full Text] [Related]
9. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
[TBL] [Abstract][Full Text] [Related]
10. Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon.
Marasini B; Massarotti M; Bottasso B; Coppola R; Del Papa N; Maglione W; Comina DP; Maioli C
Scand J Rheumatol; 2004; 33(4):253-6. PubMed ID: 15370722
[TBL] [Abstract][Full Text] [Related]
11. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous laser doppler flux distribution in ischemic ulcers and the effect of prostanoids: a crossover study comparing the acute action of prostaglandin E1 and iloprost vs saline.
Gschwandtner ME; Koppensteiner R; Maca T; Minar E; Schneider B; Schnürer G; Ehringer H
Microvasc Res; 1996 Jan; 51(1):29-38. PubMed ID: 8812752
[TBL] [Abstract][Full Text] [Related]
13. Iloprost treatment for refractory Raynaud's phenomenon in two infants.
Shouval DS; Mukamel M; Zulian F; Amir J; Harel L
Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S105-7. PubMed ID: 18799065
[TBL] [Abstract][Full Text] [Related]
14. Iloprost infusion through elastomeric pump for the outpatient treatment of severe Raynaud's phenomenon and digital ulcers - a single centre experience.
Duarte AC; Barbosa L; Santos MJ; Cordeiro A
Acta Reumatol Port; 2018; 43(3):237-238. PubMed ID: 30414374
[TBL] [Abstract][Full Text] [Related]
15. Is iloprost effective in secondary Raynaud's phenomenon?
Lustig N; Rada G
Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330
[TBL] [Abstract][Full Text] [Related]
16. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
[TBL] [Abstract][Full Text] [Related]
17. Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study.
Bali G; Schwantzer G; Aberer F; Kraenke B; Aberer E
Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(1):13-21. PubMed ID: 21879200
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases.
Zulian F; Corona F; Gerloni V; Falcini F; Buoncompagni A; Scarazatti M; Martini G; Zacchello F
Rheumatology (Oxford); 2004 Feb; 43(2):229-33. PubMed ID: 12923288
[TBL] [Abstract][Full Text] [Related]
19. Treatment of vasculitic leg ulcers in connective tissue disease with iloprost.
Veale DJ; Muir AH; Morley KD; Belch JJ
Clin Rheumatol; 1995 Mar; 14(2):187-90. PubMed ID: 7540526
[TBL] [Abstract][Full Text] [Related]
20. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
Foti R; Visalli E; Amato G; Benenati A; Converso G; Farina A; Bellofiore S; Mulè M; Di Gangi M
Rheumatol Int; 2017 Feb; 37(2):245-249. PubMed ID: 27796521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
